

FILE 'HCAOLD' ENTERED AT 10:07:38 ON 16 SEP 2002
L58 0 S L51 OR L57

FILE 'HCAPLUS' ENTERED AT 10:07:44 ON 16 SEP 2002
L59 10 S L51 OR L57
L60 4 S L59 AND L4-L21
L61 9 S L59 AND (PD<=19991022 OR PRD<=19991022 OR AD<=19991022)
L62 3 S L60 AND L61
L63 1 S L60 NOT L62
L64 10 S L60-L63

FILE 'USPATFULL, USPAT2' ENTERED AT 10:50:26 ON 16 SEP 2002
L65 9 S L51 OR L57

FILE 'HCAPLUS, USPATFULL' ENTERED AT 10:50:48 ON 16 SEP 2002
L66 18 DUP REM L64 L65 (1 DUPLICATE REMOVED)

=> fil reg

FILE 'REGISTRY' ENTERED AT 10:51:13 ON 16 SEP 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 American Chemical Society (ACS)

STRUCTURE FILE UPDATES: 15 SEP 2002 HIGHEST RN 451445-11-7
DICTIONARY FILE UPDATES: 15 SEP 2002 HIGHEST RN 451445-11-7

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

Please note that search-term pricing does apply when
conducting SmartSELECT searches.





Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP
PROPERTIES for more information. See STNote 27, Searching Properties
in the CAS Registry File, for complete details:
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=> d sta que 132

L1 STR


Jan Delaval
Reference Librarian
Biotechnology & Chemical Library
CM1 1E07 - 703-308-4498
jan.delaval@uspto.gov



VAR G1=OH/30/31/35/44
 NODE ATTRIBUTES:
 NSPEC IS RC AT 12
 CONNECT IS M1 RC AT 12
 DEFAULT MLEVEL IS ATOM
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
 RSPEC 17 5 39
 NUMBER OF NODES IS 42

STEREO ATTRIBUTES: NONE
 L3 3613 SEA FILE=REGISTRY CSS FUL L1
 L29 STR



VAR G1=OH/30/31/35/44
 REP G2=(0-5) CH2
 VAR G3=46/48/53
 NODE ATTRIBUTES:
 CONNECT IS M1 RC AT 47
 CONNECT IS M1 RC AT 49
 CONNECT IS M1 RC AT 54
 DEFAULT MLEVEL IS ATOM
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
 RSPEC 39 7 17
 NUMBER OF NODES IS 50

STEREO ATTRIBUTES: NONE
 L32 323 SEA FILE=REGISTRY SUB=L3 CSS FUL L29

100.0% PROCESSED 3613 ITERATIONS
 SEARCH TIME: 00.00.08

323 ANSWERS

=> d his

(FILE 'HOME' ENTERED AT 09:16:06 ON 16 SEP 2002)
 SET COST OFF

FILE 'REGISTRY' ENTERED AT 09:16:27 ON 16 SEP 2002
 L1 STR
 L2 50 S L1 CSS
 L3 3613 S L1 CSS FUL
 SAV L3 QAZI035/A

FILE 'HCAPLUS' ENTERED AT 09:22:03 ON 16 SEP 2002
 E TAKENOUCHI K/AU

L4 36 S E3,E14
 E GAO Q/AU
 L5 77 S E3,E10
 E GAO QING/AU
 L6 81 S E3,E17
 L7 15 S E61
 E MANABE K/AU
 L8 39 S E3
 E MANABE KEN/AU
 L9 102 S E6
 E SOGAWA R/AU
 L10 4 S E4
 E TAKANO Y/AU
 L11 228 S E3,E4,E11
 L12 34 S E14
 E ISHIZUKA S/AU
 L13 149 S E3,E11
 E TEIJIN/PA,CS
 L14 18629 S E1-E4
 E WO99-JP4826/AP,PRN
 E WO99-JP5826/AP,PRN
 L15 1 S E3,E4
 E JP98-365209/AP,PRN
 L16 1 S E4
 L17 1 S E2
 L18 1 S E1
 E JP98-362827/AP,PRN
 L19 1 S E4
 E JP98-302321/AP,RPN
 E JP98-302321/AP,PRN
 L20 1 S E4
 L21 1 S L4-L14 AND L15-L20
 SEL RN
 SEL RN

FILE 'REGISTRY' ENTERED AT 09:26:09 ON 16 SEP 2002

L22 182 S E1-E182
 L23 70 S L22 AND L3
 L24 112 S L22 NOT L23
 L25 58 S L23 AND NR>=4
 L26 12 S L23 NOT L25
 L27 STR L1
 L28 22 S L27 SAM SUB=L3
 L29 STR L27
 L30 14 S L29 CSS SAM SUB=L3
 L31 8 S L28 NOT L30
 L32 323 S L29 CSS FUL SUB=L3
 SAV L32 QAZI035A/A
 L33 57 S L23 AND L32
 L34 1 S L25 NOT L33
 L35 35 S L32 AND S/ELS
 L36 288 S L32 NOT L35
 L37 65 S L36 AND N>=2
 L38 223 S L36 NOT L37
 L39 166 S L38 NOT L33,L34
 L40 7 S L39 AND N/ELS
 L41 159 S L39 NOT L40
 L42 11 S L41 AND C3/ES
 L43 148 S L41 NOT L42
 L44 138 S L43 NOT 46.150.18/RID
 L45 123 S L44 NOT OC2/ES
 L46 50 S L45 AND (OC3 OR OC4 OR OC5 OR OCOC2 OR OCOC3)/ES
 L47 73 S L45 NOT L46

L48 71 S L47 NOT O2C4/ES
 L49 9 S L48 AND SI/ELS
 L50 3 S L49 AND (C48H86O4SI3 OR C47H88O3SI3 OR C37H66O3SI3)
 L51 68 S L48 NOT L50
 SAV L51 QAZI035B/A
 L52 58 S L33,L34
 L53 15 S L52 AND (OC4 OR OC5)/ES
 L54 43 S L52 NOT L53
 L55 38 S L54 NOT ?SPIRO?/CNS
 L56 3 S L55 AND (NC5/ES OR C41H70O5SI2 OR C42H74O5SI2)
 L57 35 S L55 NOT L56
 SAV L57 QAZI035C/A

FILE 'HCAOLD' ENTERED AT 10:07:38 ON 16 SEP 2002

L58 0 S L51 OR L57

FILE 'HCAPLUS' ENTERED AT 10:07:44 ON 16 SEP 2002

L59 10 S L51 OR L57
 L60 4 S L59 AND L4-L21
 L61 9 S L59 AND (PD<=19991022 OR PRD<=19991022 OR AD<=19991022)
 L62 3 S L60 AND L61
 L63 1 S L60 NOT L62
 L64 10 S L60-L63

FILE 'USPATFULL, USPAT2' ENTERED AT 10:50:26 ON 16 SEP 2002

L65 9 S L51 OR L57

FILE 'HCAPLUS, USPATFULL' ENTERED AT 10:50:48 ON 16 SEP 2002

L66 18 DUP REM L64 L65 (1 DUPLICATE REMOVED)

FILE 'REGISTRY' ENTERED AT 10:51:13 ON 16 SEP 2002

=> fil hcaplus uspatall

FILE 'HCAPLUS' ENTERED AT 10:51:36 ON 16 SEP 2002

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 10:51:36 ON 16 SEP 2002

CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 10:51:36 ON 16 SEP 2002

CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

=> d l66 bib abs hitrn fhitrstr retable tot

L66 ANSWER 1 OF 18 HCAPLUS COPYRIGHT 2002 ACS DUPLICATE 1

AN 1990:21201 HCAPLUS

DN 112:21201

TI Preparation of cyclopentano vitamin D analogs for regulating calcium transport and bone resorption and for inducing cell differentiation (antineoplastics)

IN DeLuca, Hector F.; Schnoes, Heinrich K.; Perlman, Kato L.; Kutner, Andrzej

PA Wisconsin Alumni Research Foundation, USA

SO U.S., 7 pp.

CODEN: USXXAM

DT Patent


LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 4851401	A	19890725	US 1988-219101	19880714 <--
	WO 9000541	A1	19900125	WO 1989-US1634	19890418 <--

W: AU, CH, DE, DK, GB, HU, JP, KR, NL, SU
 RW: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE

AU 8934385	A1	19900205	AU 1989-34385	19890418 <--
AU 612029	B2	19910627		
EP 407461	A1	19910116	EP 1989-905008	19890418 <--
EP 407461	B1	19930331		
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
JP 03501259	T2	19910322	JP 1989-504822	19890418 <--
AT 87618	E	19930415	AT 1989-905008	19890418 <--
GB 2220660	A1	19900117	GB 1989-9571	19890426 <--
FR 2634200	A1	19900119	FR 1989-5754	19890428 <--
PRAI US 1988-219101		19880714	<--	
EP 1989-905008		19890418	<--	
WO 1989-US1634		19890418	<--	
OS MARPAT 112:21201				
GI				




AB The title compds. [I; R1, R2, R3 = H, protecting group; X = H, PhSO2; Y = H, (protected) OH, or XY = bond], useful for regulating Ca transport in the intestine and Ca resorption from bone, and for treating neoplastic diseases, are prepd. I (R1 = R2 = R3 = X = Y = H) (II) was prepd. via an intermediary Ph sulfone deriv. (starting materials and intermediates are not specified in the disclosure). II at 125 ng/day produced a >4-fold increase in Ca transport and 2-fold increase in serum Ca in test rats compared with controls; both calcemic and differentiation-inducing activities of II were greater than those of 1,25-dihydroxyvitamin D3.

IT **114694-10-9P**
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of, for regulation of calcium metab. and as antineoplastic)

IT **114694-10-9P**
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of, for regulation of calcium metab. and as antineoplastic)

RN 114694-10-9 HCAPLUS

CN 9,10-Secochola-5,7,10(19)-triene-1,3-diol, 24-(1-hydroxycyclopentyl)-, (1.alpha.,3.beta.,5Z,7E)- (9CI) (CA INDEX NAME)



L66 ANSWER 2 OF 18 HCAPLUS COPYRIGHT 2002 ACS

AN 2002:157566 HCAPLUS

DN 136:194682

TI Use of vitamin D derivatives as bone resorption inhibitors

IN **Ishizuka, Seiichi; Takenouchi, Kazuya;** Imaizumi, Atsushi; Oue, Yasuhiro; Kurihara, Noriyoshi; Reddy, Sakamuri V.; Roodman, G. David

PA **Teijin** Limited, Japan; University of Texas, Health Science Center

SO PCT Int. Appl., 29 pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002015894	A2	20020228	WO 2001-US22614	20010822
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				
	CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,				
	GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,				
	LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL,				
	PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG,				
	US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,				
	DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,				
	BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	JP 2002069003	A2	20020308	JP 2000-252177	20000823
	AU 2001084657	A5	20020304	AU 2001-84657	20010822
PRAI	JP 2000-252177	A	20000823		
	JP 2000-2000252177A		20000823		
	WO 2001-US22614	W	20010822		
OS	MARPAT 136:194682				
GI					



AB To obtain a bone resorption inhibitor or a treating agent for Paget's disease of bone, there are provided a method of inhibiting bone resorption, comprising administering to a patient a vitamin D antagonist; and a method for treating Paget's disease of bone, comprising administering to a patient a vitamin D antagonist. An example is given showing osteoclast formation suppression activity of I on the osteoclast formation induced by 1.alpha.,25-dihydroxyvitamin D3 from bone marrow cells of normal persons.

IT **401593-62-2**

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(vitamin D derivs. as bone resorption inhibitors)


IT **401593-62-2**

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(vitamin D derivs. as bone resorption inhibitors)

RN 401593-62-2 HCAPLUS

CN Cyclopentanone, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]-2-methylene- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



DN 132:322032
 TI Preparation of vitamin D3 derivatives and remedies for inflammatory
 respiratory diseases containing the same
 IN Takenouchi, Kazuya; Gao, Qingzhi; Manabe,
 Kenji; Sogawa, Ryo; Takano, Yasuhiro;
 Ishizuka, Seiichi
 PA Teijin Limited, Japan
 SO PCT Int. Appl., 145 pp.
 CODEN: PIXXD2
 DT Patent
 LA Japanese
 FAN.CNT 1

Inventors

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000024712	A1	20000504	WO 1999-JP5826	19991022 <--
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 9962281	A1	20000515	AU 1999-62281	19991022 <--
	EP 1123921	A1	20010816	EP 1999-949355	19991022 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	US 2002091109	A1	20020711	US 2002-35219	20020104 <--
	US 2002099039	A1	20020725	US 2002-35211	20020104 <--
	US 2002103173	A1	20020801	US 2002-35217	20020104 <--
PRAI	JP 1998-302321	A	19981023	<--	
	JP 1998-362827	A	19981221	<--	
	JP 1998-365207	A	19981222	<--	
	JP 1998-365208	A	19981222	<--	
	JP 1998-365209	A	19981222	<--	
	WO 1999-JP5826	W	19991022	<--	
	US 2001-830167	A3	20010423		
OS	MARPAT 132:322032				
GI					

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Compds. represented by general formula (I) [wherein R01, R02 being each independently = hydrogen, Me3Si, Et3Si, tert-BuMe2Si, Ac, MeOCH2, or tetrahydro-4H-pyran-2-yl; and Z = a group represented by general formula Q1, Q2, Q3, Q4, (CH2)3C(OH)R51R52; wherein m, n = 0, 2; R11, R12 = H, C1-4 alkyl; K = L = M = H; M = H, K and L together form a double bond together with the existing single bond; K = H, L and M together form a double bond together with the existing single bond; CR21R22 = C3-6 cycloalkyl; Q = CFR31, NR31; R21, R22, R23, R31, R45, R46 = H, HO, CO2H, CF3, pentafluoroethyl, C1-4 alkyloxycarbonyl, C2-5 acyloxy, etc.; R32-R35 = H, OH, C1-4 alkyl, C2-5 acyloxy; A, B = H, OH; A and B together form a double bond together with the existing single bond; CXY = CO; one of X and Y = H, the other = OH or C2-5 acyloxy; R41, R42, R43, R44 = H, HO, CF3, pentafluoroethyl, C2-6 acyloxy, C1-4 alkoxy, etc.; D = E = H; D = OH, E = H; D and E or E and R41 together form a double bond together with the existing single bond; R42 = H, HO, CF3, pentafluoroethyl, C2-5 acyloxy, C1-4 alkoxy, etc.; R51 = (un)substituted CONH2, COR55, C(OH)R56R57; R55, R56, R57 = C1-4 alkyl; R52 = Me, Et, CF3, pentafluoroethyl] are prepd.

These compds. are useful as active ingredients of the remedies for inflammatory respiratory diseases, malignant tumor, articular rheumatism, osteoporosis, true diabetes, hypertension, alopecia, acne, psoriasis, dermatitis, hypercalcemia, hypofunction of accessory thyroid, or metabolic disorder of cartilage. Thus, intermediate (II) was coupled with (3S,5R)-3,5-bis(trimethylsilyloxy)-1-octen-7-yne in the presence of Ph3P and tris(dibenzylideneacetone)dipalladium-chloroform adduct in PhMe at 100.degree. for 6 h followed by treatment with lithium tetrafluoroborate and H2SO4 in MeCN for 20 min to give title compd. (III). III, administered at 1-20 .mu.g/kg to air way of golden hamster, inhibited 20-40% neutrophil infiltration in a LPS-induced pneumonia model. A tablet formulation contg. III was prepd.

IT 266343-22-0P 266343-23-1P 266343-75-3P
 266343-85-5P 266343-88-8P 266343-91-3P
 266343-93-5P 266344-00-7P 266344-11-0P
 266344-17-6P 266344-23-4P 266344-26-7P
 266344-35-8P 266344-38-1P 266344-39-2P
 266344-40-5P 266344-54-1P 266344-58-5P
 266344-60-9P 266344-61-0P 266344-64-3P
 266344-65-4P 266344-66-5P 266344-67-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of vitamin D3 derivs. as remedies for inflammatory respiratory diseases and other diseases)

IT 266343-73-1P 266343-74-2P 266343-78-6P
 266343-81-1P 266343-82-2P 266344-05-2P
 266344-08-5P 266344-14-3P 266344-20-1P
 266344-29-0P 266344-32-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of vitamin D3 derivs. as remedies for inflammatory respiratory diseases and other diseases)

IT 266343-22-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(prepn. of vitamin D3 derivs. as remedies for inflammatory respiratory diseases and other diseases)

RN 266343-22-0 HCAPLUS

CN 2-Pyrrolidinone, 5-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]-3-methylene-, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Chugai Pharmaceutical C	1995			JP 07173133 A	HCAPLUS
Teijin Limited				JP 06329696 A	HCAPLUS
Teijin Limited				US 5604257 A	HCAPLUS
Teijin Limited				EP 970948 A1	HCAPLUS
Teijin Limited	1994			EP 619305 A1	HCAPLUS
Teijin Limited	1998			WO 9858909 A1	HCAPLUS
Teikoku Hormone Mfg Co	1999			JP 1149747 A	

L66 ANSWER 4 OF 18 HCAPLUS COPYRIGHT 2002 ACS

AN 1999:27811 HCAPLUS

DN 130:81699

TI Preparation of vitamin D3 derivatives as remedies for inflammatory respiratory diseases and other disorders

IN Tanaka, Hiroko; Gao, Qingzhi; Manabe, Kenji; Furuya, Minoru; Tabe, Masayasu; Ishizuka, Seiichi; Chokki, Manabu; Mitsuhashi, Hiroaki; Kishimoto, Tadashi; Hazato, Atsuo; Sakuma, Yasuji

PA Teijin Limited, Japan

SO PCT Int. Appl., 117 pp.

CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9858909	A1	19981230	WO 1998-JP2813	19980624 <--
	W: AU, CA, CN, JP, KR, US				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	AU 9879328	A1	19990104	AU 1998-79328	19980624 <--
	AU 743399	B2	20020124		
	EP 970948	A1	20000112	EP 1998-929661	19980624 <--
	R: AT, BE, CH, DE, ES, FR, GB, IT, LI, NL, SE				
	US 6028208	A	20000222	US 1999-242665	19990222 <--
PRAI	JP 1997-168803	A	19970625	<--	
	WO 1998-JP2813	W	19980624	<--	
OS	MARPAT 130:81699				
GI					

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Vitamin D3 derivs. [I; R1, R2 = H, trialkylsilyl, etc.; Z = Q, Q1, Q2; R3, R4 = H, OH, etc.; R5-R8 = H, OH, alkyl, acyloxy; R9 = H, OH, alkyl, alkylthio; R10 = H, alkyl, alkoxy; A, B = H, OH, etc.; X, Y = carbonyl oxygen, or one of X and Y = H while another = OH, etc.; X1 = (CH2)n; X2 = (CH2)m; n, m = 0-2; X3 = (CR7R8)m], useful for treatment of inflammatory respiratory diseases, malignant tumors, articular rheumatism, osteoporosis, diabetes mellitus, hypertension, baldness, acne, psoriasis, and dermatitis, are prepd. Thus, II [R11 = CHO] was reacted with 2-ethyl-2-hydroxy-2-cyclopentanone in ethanol contg. KOH to give a mixt. of all 4 possible stereoisomers of the final product [II; R11 = Q3]. One of these stereoisomers showed >40% inhibitor of neutrocyte infiltration in induced pneumonia in hamsters. Pharmaceutical compns. contg. I are described.

IT 218437-01-5P 218437-02-6P 218437-03-7P
 218437-04-8P 218437-05-9P 218437-06-0P
 218437-07-1P 218437-08-2P 218437-09-3P
 218437-10-6P 218437-11-7P 218437-13-9P
 218437-15-1P 218437-17-3P 218437-19-5P
 218437-21-9P 218437-23-1P 218437-24-2P
 218437-25-3P 218437-30-0P 218437-31-1P
 218437-32-2P 218437-33-3P 218437-34-4P
 218437-35-5P 218437-36-6P 218437-37-7P
 218437-38-8P 218437-39-9P 218437-40-2P
 218437-41-3P 218437-42-4P 218437-43-5P
 218437-44-6P 218437-45-7P 218437-46-8P
 218437-47-9P 218437-48-0P 218437-49-1P
 218437-50-4P 218437-51-5P 218437-52-6P
 218437-53-7P 218437-54-8P 218437-55-9P
 218437-56-0P 218437-57-1P 218437-58-2P
 218437-59-3P 218437-60-6P 218437-61-7P
 218437-62-8P 218437-63-9P 218437-64-0P
 218437-65-1P 218437-66-2P 218437-67-3P
 218598-74-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of vitamin D3 derivs. as remedies for inflammatory respiratory diseases and other disorders)

IT 218437-81-1P 218437-86-6P 218437-95-7P
 218437-96-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (prepn. of vitamin D3 derivs. as remedies for inflammatory respiratory diseases and other disorders)


IT 218437-01-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of vitamin D3 derivs. as remedies for inflammatory respiratory diseases and other disorders)

RN 218437-01-5 HCAPLUS

CN Cyclopentanone, 5-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-2-ethyl-2-hydroxy-, (2R,5E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry, as shown.



RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Leo Pharmaceutical Prod				EP 412110 A1	HCAPLUS
Leo Pharmaceutical Prod				US 5206229 A	HCAPLUS
Leo Pharmaceutical Prod				WO 8910351 A1	HCAPLUS
Leo Pharmaceutical Prod	1991			JP 03504377 A	
Teijin Ltd				US 5719297 A	HCAPLUS
Teijin Ltd				EP 712843 A1	HCAPLUS
Teijin Ltd				WO 9533716 A1	HCAPLUS
Teijin Ltd	1996			JP 853411 A	

L66 ANSWER 5 OF 18 HCAPLUS COPYRIGHT 2002 ACS

AN 1996:102562 HCAPLUS

DN 124:146588

TI Preparation of vitamin D3 derivatives

IN Tabe, Masayasu; Hazato, Atsuo; Manabe, Kenji; Gao, Qingzhi; Tanaka, Hiroko

PA Teijin Ltd., Japan

SO PCT Int. Appl., 156 pp.

CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9533716	A1	19951214	WO 1995-JP1145	19950607 <--
	W: CA, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	JP 08053411	A2	19960227	JP 1995-137821	19950605 <--
	CA 2168728	AA	19951214	CA 1995-2168728	19950607 <--
	EP 712843	A1	19960522	EP 1995-921131	19950607 <--
	EP 712843	B1	19991117		
	R: AT, BE, CH, DE, ES, FR, GB, IT, LI, NL, SE				
	EP 854138	A2	19980722	EP 1998-101653	19950607 <--
	EP 854138	A3	19980923		
	EP 854138	B1	20010523		
	R: AT, BE, CH, DE, ES, FR, GB, IT, LI, NL, SE				
	EP 854139	A2	19980722	EP 1998-101654	19950607 <--
	EP 854139	A3	19980923		
	EP 854139	B1	20010905		
	R: AT, BE, CH, DE, ES, FR, GB, IT, LI, NL, SE				
	AT 186721	E	19991215	AT 1995-921131	19950607 <--
	ES 2138212	T3	20000101	ES 1995-921131	19950607 <--

	AT 205190	E	20010915	AT 1998-101654	19950607 <--
	JP 08143541	A2	19960604	JP 1995-144474	19950612 <--
	JP 08134052	A2	19960528	JP 1995-147168	19950614 <--
	US 5719297	A	19980217	US 1996-591547	19960206 <--
	US 5986112	A	19991116	US 1997-971201	19971114 <--
	US 6177586	B1	20010123	US 1999-327489	19990608 <--
PRAI	JP 1994-125144	A	19940607 <--		
	JP 1994-220185	A	19940914 <--		
	JP 1994-223229	A	19940919 <--		
	EP 1995-921131	A3	19950607 <--		
	WO 1995-JP1145	W	19950607 <--		
	US 1996-591547	A3	19960206 <--		
	US 1997-971201	A3	19971114 <--		
OS	MARPAT 124:146588				
GI					

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. [I; R = H, C1-7 hydrocarbylsilyl, C2-8 acyl, acetal residue; A = hydroxymethylcyclopentenyl, methyloxotetrahydro-2-furyl, (un)substituted 3-carboxy-3-hydroxybutyl] are prepd. Thus, II (prepn. given) was reacted with III in CHCl₃ contg. tris(dibenzylideneacetone)dipalladium followed by deprotection to give the title compd. I [R = H, A = (2S,4S)-4-methyl-5-oxotetrahydro-2-furyl]. This bound with the 1.alpha.,25-dihydroxyvitamin D₃ receptor at a mol ratio of 104:1 compared with 1:1 for 1.alpha.,25-dihydroxyvitamin D₃.

IT 173388-33-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of vitamin D₃ derivs.)


IT 173388-33-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of vitamin D₃ derivs.)

RN 173388-33-5 HCAPLUS


CN 1,3-Cyclohexanediol, 4-methylene-5-[[octahydro-1-[2-(4-hydroxy-4-methyl-2-cyclopenten-1-yl)-1-methylethyl]-7a-methyl-4H-inden-4-ylidene]ethylidene]-, [1R-[1.alpha.[R*(1S*,4R*)],3a.beta.,4E[Z(1R*,3S*)],7a.alpha.]]- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L66 ANSWER 6 OF 18 HCAPLUS COPYRIGHT 2002 ACS
 AN 1993:525211 HCAPLUS
 DN 119:125211
 TI Treatment of asthma with vitamin D3 derivatives
 IN Godtfredsen, Wagn Ole
 PA Leo Pharamceutical Products Ltd. A/S, Den.
 SO Brit. UK Pat. Appl., 17 pp.
 CODEN: BAXXDU
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	GB 2260904	A1	19930505	GB 1992-26958	19921224 <--
PRAI	GB 1992-3535		19920219 <--		
AB	1,25-Dihydroxyvitamin D3 derivs. are effective for the treatment of asthma. The medicaments may be dispensed in a spray can, nebulizer, or atomizer. A nebulizer soln. contg. MC 903 2 mg/1000 mL was formulated.				
IT	128312-74-3 RL: BIOL (Biological study) (asthma treatment with)				
IT	128312-74-3 RL: BIOL (Biological study) (asthma treatment with)				
RN	128312-74-3 HCAPLUS				
CN	9,10-Secochola-5,7,10(19)-triene-1,3-diol, 24-(1-hydroxycyclohexyl)-, (1.alpha.,3.beta.,5Z,7E)- (9CI) (CA INDEX NAME)				



L66 ANSWER 7 OF 18 HCAPLUS COPYRIGHT 2002 ACS
 AN 1993:524825 HCAPLUS
 DN 119:124825
 TI Hair preparations containing vitamin D3 analogs for treatment of alopecia
 IN Godtfredsen, Wagn Ole
 PA Leo Pharmaceutical Products Ltd. A/S, Den.
 SO Brit. UK Pat. Appl., 11 pp.
 CODEN: BAXXDU
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	GB 2260903	A1	19930505	GB 1992-26957	19921224 <--
PRAI	GB 1992-1920		19920129 <--		
AB	1,25-Dihydroxyvitamin D3 derivs. are effective for the prevention and				

treatment of alopecia. A cream contg. MC 903 10 .mu.g/g was formulated.

IT 128312-74-3


RL: BIOL (Biological study)
(alopecia treatment with)

IT 128312-74-3

RL: BIOL (Biological study)
(alopecia treatment with)

RN 128312-74-3 HCAPLUS

CN 9,10-Secochola-5,7,10(19)-triene-1,3-diol, 24-(1-hydroxycyclohexyl)-,
(1.alpha.,3.beta.,5Z,7E)- (9CI) (CA INDEX NAME)



L66 ANSWER 8 OF 18 HCAPLUS COPYRIGHT 2002 ACS

AN 1991:464738 HCAPLUS

DN 115:64738

TI Use of vitamin D compounds to inhibit AIDS virus

IN Pauza, Charles David; Deftos, Leonard John; Deluca, Hector Floyd

PA Wisconsin Alumni Research Foundation, USA

SO PCT Int. Appl., 81 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9103246	A1	19910321	WO 1990-US5134	19900910 <--
	W: AU, BR, CA, JP, KR				
	RW: AT, BE, BF, BJ, CF, CG, CH, CM, DE, DK, ES, FR, GA, GB, IT, LU, ML, MR, NL, SE, SN, TD, TG				
	CA 2042369	AA	19910312	CA 1990-2042369	19900910 <--
	AU 9064418	A1	19910408	AU 1990-64418	19900910 <--
	EP 443021	A1	19910828	EP 1990-914580	19900910 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, LU, NL, SE				
	JP 04505332	T2	19920917	JP 1990-513750	19900910 <--
	ZA 9007228	A	19910731	ZA 1990-7228	19900911 <--
PRAI	US 1989-405857		19890911	<--	
	US 1990-579341		19900907	<--	
	WO 1990-US5134		19900910	<--	
OS	MARPAT 115:64738				
GI					

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. include I [R₄,R₅ = H, D, or R₄R₅ = double or triple bond; R₃,R₁₃ = H, (protected) OH, F, D, alkyl; Z = H, (protected) OH; X,Y = H, hydroxy-protecting group; R₁ = CF₃, CD₃, (CH₂)_qH (q = 1-5); R₂ = CF₃, CD₃, (CH₂)_pH (p = 1-5), or R₁R₂ = (CH₂)_m (M = 2-5); n = 1-5], II (X₁,Y₁ = H, acyl, alkylsilyl, alkoxyalkyl; U = H, alkyl, hydroxyalkyl, etc.), and III (R₂ = H, Me, Et, propyl; X₂,Y₂ = H, acyl, hydroxy-protecting group). The vitamin D derivs. of the invention inhibit replication of human immunodeficiency virus in human cells and are therefore useful for treatment of AIDS. The compds. are also useful for treating other lentivirus infections and attendant immune and infectious disorders. Prepn. of selected compds. is described. The derivs. of the invention were also studied with regard to cell differentiation activity and Ca mobilization/transport. For example, cyclopentano-1,25-dihydroxy-vitamin D₃ (IV) and cyclopentano-1,25-dihydroxy-22E-dehydro-vitamin D₃ (V) increased intestinal Ca transport and bone Ca mobilization (serum Ca levels detd.). IV and V were also more active than 1,25-dihydroxy-vitamin D₃ in inducing differentiation of HL-60 leukemic cells, making them useful not only as Ca regulating agents but also in the treatment of neoplastic diseases, esp. leukemias. Biol. activity of a variety of other vitamin D derivs. is given.

IT 128312-74-3


RL: BIOL (Biological study)
(calcium mobilization and leukemic cell line HL-60 differentiation stimulation activity of)

IT 128312-74-3

RL: BIOL (Biological study)
(calcium mobilization and leukemic cell line HL-60 differentiation stimulation activity of)

RN 128312-74-3 HCAPLUS

CN 9,10-Secochola-5,7,10(19)-triene-1,3-diol, 24-(1-hydroxycyclohexyl)-, (1.alpha.,3.beta.,5Z,7E)- (9CI) (CA INDEX NAME)



L66 ANSWER 9 OF 18 HCAPLUS COPYRIGHT 2002 ACS

AN 1990:478822 HCAPLUS

DN 113:78822

TI Preparation of vitamin D analogs as drugs

IN Calverley, Martin John; Binderup, Lise; Binderup, Ernst Torndal

PA Leo Pharmaceutical Products Ltd., Den.

SO PCT Int. Appl., 59 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----

```

PI   WO 8910351      A1  19891102      WO 1989-DK79      19890407 <--
      W: AU, DK, JP, KR, US
      RW: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE
      AU 8935443      A1  19891124      AU 1989-35443      19890407 <--
      AU 614372       B2  19910829
      EP 412110       A1  19910213      EP 1989-905648     19890407 <--
      EP 412110       B1  19930707
      R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE
      JP 03504377     T2  19910926      JP 1989-504872     19890407 <--
      AT 91282        E   19930715      AT 1989-905648     19890407 <--
      ZA 8902824      A   19911127      ZA 1989-2824       19890418 <--
      DK 9002426      A   19901008      DK 1990-2426       19901008 <--
      DK 173457       B1  20001127
      US 5206229      A   19930427      US 1990-582944     19901010 <--
PRAI GB 1988-9466    A   19880421 <--
      GB 1988-9467    A   19880421 <--
      GB 1988-30169   A   19881223 <--
      GB 1988-30174   A   19881223 <--
      EP 1989-905648  A   19890407 <--
      WO 1989-DK79    A   19890407 <--
OS   MARPAT 113:78822
GI


```

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

```

AB   The title compds. [I; n = 1-7; R1, R2 = H, alkyl; or CR1R2 may form a
      carbocyclic ring; R3 = R4 = H; or R3R4 = double bond], useful as
      immunostimulants, antidiabetics, antihypertensives, antiinflammatories (no
      data), etc., are prepd. Thus, a 9,10-secosteroid deriv. II was heated
      with Bu4NF in THF at 60.degree. and the resulting diol III was heated with
      pyridinium p-toluenesulfonate in EtOH at 50.degree. to give I [R1R2 =
      (CH2)2, R3 = R4 = H, n = 1]. A dermatol. cream and an oral capsule contg.
      I as the active ingredient were formulated.
IT   128312-74-3P
      RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological
      study); PREP (Preparation); USES (Uses)
      (prepn. of, as drug)
IT   128312-98-1P 128332-75-2P
      RL: SPN (Synthetic preparation); PREP (Preparation)
      (prepn. of, as intermediate for vitamin D analogs)
IT   128312-74-3P
      RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological
      study); PREP (Preparation); USES (Uses)
      (prepn. of, as drug)
RN   128312-74-3 HCAPLUS
CN   9,10-Secochola-5,7,10(19)-triene-1,3-diol, 24-(1-hydroxycyclohexyl)-,
      (1.alpha.,3.beta.,5Z,7E)- (9CI) (CA INDEX NAME)

```



L66 ANSWER 10 OF 18 HCAPLUS COPYRIGHT 2002 ACS

AN 1988:455060 HCAPLUS

DN 109:55060

TI Novel convergent synthesis of side-chain-modified analogs of 1.alpha.,25-dihydroxycholecalciferol and 1.alpha.,25-dihydroxyergocalciferol

AU Kutner, Andrzej; Perlman, Kato L.; Lago, Amparo; Schnoes, Heinrich K.; DeLuca, H. F.; Sicinski, Rafal R.

CS Coll. Agric. Life Sci., Univ. Wisconsin, Madison, WI, 53706, USA

SO J. Org. Chem. (1988), 53(15), 3450-7

CODEN: JOCEAH; ISSN: 0022-3263

DT Journal

LA English

OS CASREACT 109:55060

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB A convergent synthesis of vitamin D3 analogs such as I (active in differentiation of human leukemia HL 60 cells with diminished calcemic activity) was developed, via the common intermediate II.

IT 114694-10-9P


RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. and antitumor activity of)

IT 114694-10-9P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. and antitumor activity of)

RN 114694-10-9 HCAPLUS

CN 9,10-Secochola-5,7,10(19)-triene-1,3-diol, 24-(1-hydroxycyclopentyl)-, (1.alpha.,3.beta.,5Z,7E)- (9CI) (CA INDEX NAME)



L66 ANSWER 11 OF 18 USPATFULL
 AN 2002:192102 USPATFULL
 TI Vitamin D3 derivative and treating agent for inflammatory respiratory disease using same
 IN Takenouchi, Kazuya, Tokyo, JAPAN
 Gao, Qingzhi, Tokyo, JAPAN
 Manabe, Kenji, Tokyo, JAPAN
 Sogawa, Ryo, Tokyo, JAPAN
 Takano, Yasuhiro, Tokyo, JAPAN
 Ishizuka, Seiichi, Tokyo, JAPAN
 PA TEIJIN LIMITED (non-U.S. corporation)
 PI US 2002103173 A1 20020801
 AI US 2002-35217 A1 20020104 (10)
 RLI Division of Ser. No. US 2001-830167, filed on 23 Apr 2001, PENDING
 PRAI JP 1998-302321 19981023
 JP 1998-362827 19981221
 JP 1998-365207 19981222
 JP 1998-365208 19981222
 JP 1998-365209 19981222
 DT Utility
 FS APPLICATION
 LREP SUGHRUE, MION, ZINN,, MACPEAK & SEAS, PLLC, Suite 800, 2100 Pennsylvania Avenue, N.W., Washington, DC, 20037-3213
 CLMN Number of Claims: 44
 ECL Exemplary Claim: 1
 DRWN No Drawings
 LN.CNT 4284
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB Compounds expressed by the following general formula (1), ##STR1##

[wherein, R.sub.01 and R.sub.02 are each independently a hydrogen atom or a protecting group for a hydroxyl group; Z is one out of the following formulae (1-1), (1-2), (1-3), (1-4) and (1-5)]. ##STR2##

The compounds can be used as active ingredients of treating agents for inflammatory respiratory diseases, malignant tumors, rheumatoid arthritis, osteoporosis, diabetes mellitus, hypertension, alopecia, acne, psoriasis, dermatitis, hypercalcemia, hypoparathyroidism and metabolic disorder of cartilage.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 IT 266343-22-0P 266343-23-1P 266343-75-3P
 266343-85-5P 266343-88-8P 266343-91-3P
 266343-93-5P 266344-00-7P 266344-11-0P
 266344-17-6P 266344-23-4P 266344-26-7P

266344-35-8P 266344-38-1P 266344-39-2P
 266344-40-5P 266344-54-1P 266344-58-5P
 266344-60-9P 266344-61-0P 266344-64-3P
 266344-65-4P 266344-66-5P 266344-67-6P

(prepn. of vitamin D3 derivs. as remedies for inflammatory respiratory diseases and other diseases)

IT 266343-73-1P 266343-74-2P 266343-78-6P
 266343-81-1P 266343-82-2P 266344-05-2P
 266344-08-5P 266344-14-3P 266344-20-1P
 266344-29-0P 266344-32-5P

(prepn. of vitamin D3 derivs. as remedies for inflammatory respiratory diseases and other diseases)

IT 266343-22-0P


(prepn. of vitamin D3 derivs. as remedies for inflammatory respiratory diseases and other diseases)

RN 266343-22-0 USPTAFULL

CN 2-Pyrrolidinone, 5-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]-3-methylene-, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



L66 ANSWER 12 OF 18 USPTAFULL

AN 2002:186118 USPTAFULL

TI Vitamin D3 derivative and treating agent for inflammatory respiratory disease using same

IN Takenouchi, Kazuya, Tokyo, JAPAN

Gao, Qingzhi, Tokyo, JAPAN

Manabe, Kenji, Tokyo, JAPAN

Sogawa, Ryo, Tokyo, JAPAN

Takano, Yasuhiro, Tokyo, JAPAN

Ishizuka, Seiichi, Tokyo, JAPAN

PA TEIJIN LIMITED (non-U.S. corporation)

PI US 2002099039 A1 20020725

AI US 2002-35211 A1 20020104 (10)

RLI Division of Ser. No. US 2001-830167, filed on 23 Apr 2001, PENDING

PRAI JP 1998-302321 19981023

JP 1998-362827 19981221

JP 1998-365207 19981222

JP 1998-365208 19981222

JP 1998-365209 19981222

DT Utility

FS APPLICATION
LREP SUGHRUE MION, PLLC, 2100 Pennsylvania Avenue, NW, Washington, DC,
20037-3213
CLMN Number of Claims: 44
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 4241

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds expressed by the following general formula (1), ##STR1##

[wherein, R.sub.01 and R.sub.02 are each independently a hydrogen atom or a protecting group for a hydroxyl group; Z is one out of the following formulae (1-1), (1-2), (1-3), (1-4) and (1-5)]. ##STR2##

The compounds can be used as active ingredients of treating agents for inflammatory respiratory diseases, malignant tumors, rheumatoid arthritis, osteoporosis, diabetes mellitus, hypertension, alopecia, acne, psoriasis, dermatitis, hypercalcemia, hypoparathyroidism and metabolic disorder of cartilage.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 266343-22-0P 266343-23-1P 266343-75-3P
266343-85-5P 266343-88-8P 266343-91-3P
266343-93-5P 266344-00-7P 266344-11-0P
266344-17-6P 266344-23-4P 266344-26-7P
266344-35-8P 266344-38-1P 266344-39-2P
266344-40-5P 266344-54-1P 266344-58-5P
266344-60-9P 266344-61-0P 266344-64-3P
266344-65-4P 266344-66-5P 266344-67-6P

(prepn. of vitamin D3 derivs. as remedies for inflammatory respiratory diseases and other diseases)

IT 266343-73-1P 266343-74-2P 266343-78-6P
266343-81-1P 266343-82-2P 266344-05-2P
266344-08-5P 266344-14-3P 266344-20-1P
266344-29-0P 266344-32-5P

(prepn. of vitamin D3 derivs. as remedies for inflammatory respiratory diseases and other diseases)

IT 266343-22-0P


(prepn. of vitamin D3 derivs. as remedies for inflammatory respiratory diseases and other diseases)

RN 266343-22-0 USPATFULL

CN 2-Pyrrolidinone, 5-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]-3-methylene-, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



L66 ANSWER 13 OF 18 USPATFULL
 AN 2002:172352 USPATFULL
 TI Vitamin D3 derivative and treating agent for inflammatory respiratory disease using same
 IN Takenouchi, Kazuya, Tokyo, JAPAN
 Gao, Qingzhi, Tokyo, JAPAN
 Manabe, Kenji, Tokyo, JAPAN
 Sogawa, Ryo, Tokyo, JAPAN
 Takano, Yasuhiro, Tokyo, JAPAN
 Ishizuka, Seiichi, Tokyo, JAPAN
 PA TEIJIN LIMITED (non-U.S. corporation)
 PI US 2002091109 A1 20020711
 AI US 2002-35219 A1 20020104 (10)
 RLI Division of Ser. No. US 2001-830167, filed on 23 Apr 2001, PENDING
 PRAI JP 1998-302321 19981023
 JP 1998-362827 19981221
 JP 1998-365207 19981222
 JP 1998-365208 19981222
 JP 1998-365209 19981222
 DT Utility
 FS APPLICATION
 LREP SUGHRUE MION, PLLC, 2100 Pennsylvania Avenue, NW, Washington, DC, 20037-3213
 CLMN Number of Claims: 44
 ECL Exemplary Claim: 1
 DRWN No Drawings
 LN.CNT 4194
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB Compounds expressed by the following general formula (1), ##STR1##

[wherein, R.sub.01 and R.sub.02 are each independently a hydrogen atom or a protecting group for a hydroxyl group; Z is one out of the following formulae (1-1), (1-2), (1-3), (1-4) and (1-5)]. ##STR2##

The compounds can be used as active ingredients of treating agents for inflammatory respiratory diseases, malignant tumors, rheumatoid arthritis, osteoporosis, diabetes mellitus, hypertension, alopecia, acne, psoriasis, dermatitis, hypercalcemia, hypoparathyroidism and metabolic disorder of cartilage.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 IT 266343-22-0P 266343-23-1P 266343-75-3P

266343-85-5P 266343-88-8P 266343-91-3P
 266343-93-5P 266344-00-7P 266344-11-0P
 266344-17-6P 266344-23-4P 266344-26-7P
 266344-35-8P 266344-38-1P 266344-39-2P
 266344-40-5P 266344-54-1P 266344-58-5P
 266344-60-9P 266344-61-0P 266344-64-3P
 266344-65-4P 266344-66-5P 266344-67-6P

(prepn. of vitamin D3 derivs. as remedies for inflammatory respiratory diseases and other diseases)

IT 266343-73-1P 266343-74-2P 266343-78-6P
 266343-81-1P 266343-82-2P 266344-05-2P
 266344-08-5P 266344-14-3P 266344-20-1P
 266344-29-0P 266344-32-5P

(prepn. of vitamin D3 derivs. as remedies for inflammatory respiratory diseases and other diseases)

IT 266343-22-0P


(prepn. of vitamin D3 derivs. as remedies for inflammatory respiratory diseases and other diseases)

RN 266343-22-0 USPTFULL

CN 2-Pyrrolidinone, 5-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]-3-methylene-, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



L66 ANSWER 14 OF 18 USPTFULL

AN 2001:11048 USPTFULL

TI Vitamin D3 derivative and production process thereof

IN Tabe, Masayasu, Hino, Japan

Hazato, Atsuo, Hino, Japan

Manabe, Kenji, Hino, Japan

Gao, Qingzhi, Hino, Japan

Tanaka, Hiroko, Hino, Japan

PA Teijin Limited, Osaka, Japan (non-U.S. corporation)

PI US 6177586 B1 20010123

AI US 1999-327489 19990608 (9)

RLI Division of Ser. No. US 1997-971201, filed on 14 Nov 1997, now patented,
 Pat. No. US 5986112 Division of Ser. No. US 1996-591547, filed on 6 Feb
 1996, now patented, Pat. No. US 5719297

PRAI JP 1994-125144 19940607

JP 1994-220185 19940914

JP 1994-223229 19940919

DT Utility
 FS Granted
 EXNAM Primary Examiner: Trinh, Ba K.
 LREP Sughrue, Mion, Zinn, Macpeak & Seas, PLLC
 CLMN Number of Claims: 9
 ECL Exemplary Claim: 1,4,7,8
 DRWN 2 Drawing Figure(s); 2 Drawing Page(s)
 LN.CNT 2887

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The starting materials for a production process of a vitamin D.sub.3 derivative are disclosed, e.g., a cyclopentene derivative represented by the formula (1-2): ##STR1##

wherein R.sub.1.sup.1 is a hydrogen atom, tri(C.sub.1 to C.sub.7 hydrocarbon) silyl group, C.sub.2 to C.sub.7 acyl group, group forming an acetal bond together with an oxygen atom of a hydroxyl group, and X.sub.1 is a bromine or iodine atom; and a heptanoic acid derivative represented by the formula (2-4): ##STR2##

wherein X.sub.2 is a bromine atom or iodine atom.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 173388-33-5P

(prepn. of vitamin D3 derivs.)

IT 173388-33-5P


(prepn. of vitamin D3 derivs.)

RN 173388-33-5 USPTFULL

CN 1,3-Cyclohexanediol, 4-methylene-5-[[octahydro-1-[2-(4-hydroxy-4-methyl-2-cyclopenten-1-yl)-1-methylethyl]-7a-methyl-4H-inden-4-ylidene]ethylidene]-, [1R-[1.alpha.[R*(1S*,4R*)],3a.beta.,4E[Z(1R*,3S*)],7a.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



L66 ANSWER 15 OF 18 USPTFULL

AN 2000:21702 USPTFULL

TI Vitamin D.sub.3 derivative and treating agent for inflammatory respiratory disease using same

IN Gao, Qingzhi, Hino, Japan
 Manabe, Kenji, Hino, Japan
 Furuya, Minoru, Hino, Japan
 Chokki, Manabu, Hino, Japan
 Mitsuhashi, Hiroaki, Hino, Japan
 Ishizuka, Seiichi, Hino, Japan

Kishimoto, Tadashi, Hino, Japan
 Tabe, Masayasu, Iwakuni, Japan
 Sakuma, Yasuji, Tokyo, Japan
 Hazato, Atsuo, Tokyo, Japan
 Tanaka, Hiroko, Palo Alto, CA, United States
 PA Teijin Limited, Osaka, Japan (non-U.S. corporation)
 PI US 6028208 20000222
 WO 9858909 19981230
 AI US 1999-242665 19990222 (9)
 WO 1998-JP2813 19980624
 19990222 PCT 371 date
 19990222 PCT 102(e) date
 PRAI JP 1997-168803 19970625
 DT Utility
 FS Granted
 EXNAM Primary Examiner: Dees, Jose' G.; Assistant Examiner: Qazi, Sabiha N.
 LREP Sughrue, Mion, Zinn, Macpeak & Seas, PLLC
 CLMN Number of Claims: 23
 ECL Exemplary Claim: 1
 DRWN 3 Drawing Figure(s); 3 Drawing Page(s)
 LN.CNT 3247
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB Provided are vitamin D.sub.3 derivatives expressed by the following general formula [1] ##STR1## [wherein, R.sub.1 and R.sub.2 are each a hydrogen atom, a trialkylsilyl group, an acetyl group, a methoxymethyl group, or a tetrahydropyranyl group; R.sub.3 and R.sub.4 are each a hydrogen atom, a hydroxyl group, an acyloxy group, an alkyloxy group, an alkylthio group or an alkyl group which is optionally substituted; R.sub.5, R.sub.6, R.sub.7 and R.sub.8 are each a hydrogen atom, a hydroxyl group, an alkyl group or an acyloxy group; R.sub.9 is a hydrogen atom, a hydroxyl group, an alkyl group or an alkylthio group; R.sub.10 is a hydrogen atom, an alkyl group or an alkyloxy group; A and B are each a hydrogen atom, a hydroxyl group, or together express a single bond; X and Y express a carbonyl oxygen, or one of them is a hydrogen atom and the other is a hydroxyl group or an acyloxy group; n is an integer of 0 to 2; m is an integer of 0 to 2], and a method for manufacturing the derivatives.

The compounds can be used as active ingredients of treating agents for inflammatory respiratory diseases, malignant tumors, rheumatoid arthritis, osteoporosis, diabetes mellitus, hypertension, alopecia, acne, psoriasis and dermatitis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 218437-01-5P 218437-02-6P 218437-03-7P
 218437-04-8P 218437-05-9P 218437-06-0P
 218437-07-1P 218437-08-2P 218437-09-3P
 218437-10-6P 218437-11-7P 218437-13-9P
 218437-15-1P 218437-17-3P 218437-19-5P
 218437-21-9P 218437-23-1P 218437-24-2P
 218437-25-3P 218437-30-0P 218437-31-1P
 218437-32-2P 218437-33-3P 218437-34-4P
 218437-35-5P 218437-36-6P 218437-37-7P
 218437-38-8P 218437-39-9P 218437-40-2P
 218437-41-3P 218437-42-4P 218437-43-5P
 218437-44-6P 218437-45-7P 218437-46-8P
 218437-47-9P 218437-48-0P 218437-49-1P
 218437-50-4P 218437-51-5P 218437-52-6P
 218437-53-7P 218437-54-8P 218437-55-9P
 218437-56-0P 218437-57-1P 218437-58-2P
 218437-59-3P 218437-60-6P 218437-61-7P
 218437-62-8P 218437-63-9P 218437-64-0P
 218437-65-1P 218437-66-2P 218437-67-3P

218598-74-4P

(prepn. of vitamin D3 derivs. as remedies for inflammatory respiratory diseases and other disorders)

IT 218437-81-1P 218437-86-6P 218437-95-7P

218437-96-8P

(prepn. of vitamin D3 derivs. as remedies for inflammatory respiratory diseases and other disorders)

IT 218437-01-5P


(prepn. of vitamin D3 derivs. as remedies for inflammatory respiratory diseases and other disorders)

RN 218437-01-5 USPTAFULL

CN Cyclopentanone, 5-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-2-ethyl-2-hydroxy-, (2R,5E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



L66 ANSWER 16 OF 18 USPTAFULL

AN 1999:146811 USPTAFULL

TI Vitamin D.sub.3 derivative and production process thereof

IN Tabe, Masayasu, Hino, Japan

Hazato, Atsuo, Hino, Japan

Manabe, Kenji, Hino, Japan

Gao, Qingzhi, Hino, Japan

Tanaka, Hiroko, Hino, Japan

PA Teijin Limited, Osaka, Japan (non-U.S. corporation)

PI US 5986112 19991116

AI US 1997-971201 19971114 (8)

RLI Division of Ser. No. US 591547

PRAI JP 1994-125144 19940607

JP 1994-220185 19940914

JP 1994-223229 19940919

DT Utility

FS Granted

EXNAM Primary Examiner: Owens, Amelia

LREP Sughrue, Mion, Zinn, Macpeak & Seas, PLLC

CLMN Number of Claims: 5

ECL Exemplary Claim: 1

DRWN 2 Drawing Figure(s); 2 Drawing Page(s)

LN.CNT 2852

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A vitamin D.sub.3 derivative represented by the following formula:

wherein, R is, independently, a hydrogen atom, tri(C.sub.1 to C.sub.7 hydrocarbon)silyl group, C.sub.2 to C.sub.8 acyl group, or group forming

an acetal bond together with an oxygen atom of a hydroxyl group, A is ##STR1## where, R.sup.1 is a methyl group or methylene group, and when R.sup.1 is a methylene group, the bond between the R.sup.1 and the 3-position of the lactone ring is a double bond, R.sup.2 is a hydrogen atom or C.sub.1 to C.sub.3 alkyl group, R.sup.3 is a hydrogen atom, or R.sup.2 and R.sup.3 together indicate a substitutable single methylene group.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 173388-33-5P

(prepn. of vitamin D3 derivs.)

IT 173388-33-5P


(prepn. of vitamin D3 derivs.)

RN 173388-33-5 USPTAFULL

CN 1,3-Cyclohexanediol, 4-methylene-5-[[octahydro-1-[2-(4-hydroxy-4-methyl-2-cyclopenten-1-yl)-1-methylethyl]-7a-methyl-4H-inden-4-ylidene]ethylidene]-, [1R-[1.alpha.[R*(1S*,4R*)],3a.beta.,4E[Z(1R*,3S*)],7a.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



L66 ANSWER 17 OF 18 USPTAFULL

AN 1998:17456 USPTAFULL

TI Vitamin D.sub.3 derivatives and production process thereof

IN Tabe, Masayasu, Hino, Japan

Hazato, Atsuo, Hino, Japan

Manabe, Kenji, Hino, Japan

Gao, Qingzhi, Hino, Japan

Tanaka, Hiroko, Hino, Japan

PA Teijin Limited, Osaka, Japan (non-U.S. corporation)

PI US 5719297 19980217

WO 9533716 19951214

AI US 1996-591547 19960206 (8)

WO 1995-JP1145 19950607

19960206 PCT 371 date

19960206 PCT 102(e) date

PRAI JP 1994-125144 19940607

JP 1994-220185 19940914

JP 1994-223229 19940919

DT Utility

FS Granted

EXNAM Primary Examiner: Owens, Amelia Averill

LREP Sughrue, Mion, Zinn, Macpeak & Seas, PLLC

CLMN Number of Claims: 15

ECL Exemplary Claim: 1
 DRWN 2 Drawing Figure(s); 2 Drawing Page(s)
 LN.CNT 2931

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A vitamin D.sub.3 derivative represented by the following formula:
 ##STR1## wherein, R is, independently, a hydrogen atom, tri(C.sub.1 to C.sub.7 hydrocarbon)silyl group, C.sub.2 to C.sub.8 acyl group, or group forming an acetal bond together with an oxygen atom of a hydroxyl group, A is ##STR2## where, R.sup.1 is a methyl group or methylene group, and when R.sup.1 is a methylene group, the bond between the R.sup.1 and the 3-position of the lactone ring is a double bond, R.sup.2 is a hydrogen atom or C.sub.1 to C.sub.3 alkyl group, R.sup.3 is a hydrogen atom, or R.sup.2 and R.sup.3 together indicate a substitutable single methylene group.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 173388-33-5P

(prepn. of vitamin D3 derivs.)


IT 173388-33-5P

(prepn. of vitamin D3 derivs.)

RN 173388-33-5 USPTAFULL

CN 1,3-Cyclohexanediol, 4-methylene-5-[[octahydro-1-[2-(4-hydroxy-4-methyl-2-cyclopenten-1-yl)-1-methylethyl]-7a-methyl-4H-inden-4-ylidene]ethylidene]-, [1R-[1.alpha.: [R*(1S*,4R*)], 3a.beta., 4E[Z(1R*,3S*)], 7a.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



L66 ANSWER 18 OF 18 USPTAFULL

AN 93:33482 USPTAFULL

TI Vitamin D analogues

IN Calverley, Martin J., Herlev, Denmark

Binderup, Lise, T.ang.strup, Denmark

Binderup, Ernst T., T.ang.strup, Denmark

PA Leo Pharmaceutical Products LTD, Ballerup, Denmark (non-U.S. corporation)

PI US 5206229 19930427

WO 8910351 19891102

AI US 1990-582944 19901010 (7)

WO 1989-DK79 19890407


19901010 PCT 371 date

19901010 PCT 102(e) date

PRAI GB 1988-9466 19880421

GB 1988-9467 19880421

GB 1988-30169 19881223
 GB 1988-30174 19881223
 DT Utility
 FS Granted
 EXNAM Primary Examiner: Lone, Werren B.
 LREP Cushman, Darby & Cushman
 CLMN Number of Claims: 10
 ECL Exemplary Claim: 1
 DRWN No Drawings
 LN.CNT 1614
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 IT 128312-74-3P
 (prepn. of, as drug)
 IT 128312-98-1P 128332-75-2P
 (prepn. of, as intermediate for vitamin D analogs)
 IT 128312-74-3P
 (prepn. of, as drug)
 RN 128312-74-3 USPATFULL
 CN 9,10-Secochola-5,7,10(19)-triene-1,3-diol, 24-(1-hydroxycyclohexyl)-,
 (1.alpha.,3.beta.,5Z,7E)- (9CI) (CA INDEX NAME)



=> fil reg
 FILE 'REGISTRY' ENTERED AT 10:52:02 ON 16 SEP 2002
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2002 American Chemical Society (ACS)

STRUCTURE FILE UPDATES: 15 SEP 2002 HIGHEST RN 451445-11-7
 DICTIONARY FILE UPDATES: 15 SEP 2002 HIGHEST RN 451445-11-7

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

Please note that search-term pricing does apply when
 conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP
 PROPERTIES for more information. See STNote 27, Searching Properties
 in the CAS Registry File, for complete details:
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=> s 151 or 157

L67 103 L51 OR L57

=> d reg tot

1	RN	401593-62-2	REGISTRY
2	RN	266344-67-6	REGISTRY
3	RN	266344-66-5	REGISTRY
4	RN	266344-65-4	REGISTRY
5	RN	266344-64-3	REGISTRY
6	RN	266344-61-0	REGISTRY
7	RN	266344-60-9	REGISTRY
8	RN	266344-58-5	REGISTRY
9	RN	266344-54-1	REGISTRY
10	RN	266344-40-5	REGISTRY
11	RN	266344-39-2	REGISTRY
12	RN	266344-38-1	REGISTRY
13	RN	266344-35-8	REGISTRY
14	RN	266344-32-5	REGISTRY
15	RN	266344-29-0	REGISTRY
16	RN	266344-26-7	REGISTRY
17	RN	266344-23-4	REGISTRY
18	RN	266344-20-1	REGISTRY
19	RN	266344-17-6	REGISTRY
20	RN	266344-14-3	REGISTRY
21	RN	266344-11-0	REGISTRY
22	RN	266344-08-5	REGISTRY
23	RN	266344-05-2	REGISTRY
24	RN	266344-00-7	REGISTRY
25	RN	266343-93-5	REGISTRY
26	RN	266343-91-3	REGISTRY
27	RN	266343-88-8	REGISTRY
28	RN	266343-85-5	REGISTRY
29	RN	266343-82-2	REGISTRY
30	RN	266343-81-1	REGISTRY
31	RN	266343-78-6	REGISTRY
32	RN	266343-75-3	REGISTRY
33	RN	266343-74-2	REGISTRY
34	RN	266343-73-1	REGISTRY
35	RN	266343-23-1	REGISTRY
36	RN	266343-22-0	REGISTRY
37	RN	218598-74-4	REGISTRY
38	RN	218437-96-8	REGISTRY
39	RN	218437-95-7	REGISTRY
40	RN	218437-86-6	REGISTRY
41	RN	218437-81-1	REGISTRY
42	RN	218437-67-3	REGISTRY
43	RN	218437-66-2	REGISTRY
44	RN	218437-65-1	REGISTRY
45	RN	218437-64-0	REGISTRY
46	RN	218437-63-9	REGISTRY
47	RN	218437-62-8	REGISTRY
48	RN	218437-61-7	REGISTRY
49	RN	218437-60-6	REGISTRY
50	RN	218437-59-3	REGISTRY
51	RN	218437-58-2	REGISTRY
52	RN	218437-57-1	REGISTRY
53	RN	218437-56-0	REGISTRY
54	RN	218437-55-9	REGISTRY
55	RN	218437-54-8	REGISTRY
56	RN	218437-53-7	REGISTRY
57	RN	218437-52-6	REGISTRY
58	RN	218437-51-5	REGISTRY
59	RN	218437-50-4	REGISTRY
60	RN	218437-49-1	REGISTRY

61	RN	218437-48-0	REGISTRY
62	RN	218437-47-9	REGISTRY
63	RN	218437-46-8	REGISTRY
64	RN	218437-45-7	REGISTRY
65	RN	218437-44-6	REGISTRY
66	RN	218437-43-5	REGISTRY
67	RN	218437-42-4	REGISTRY
68	RN	218437-41-3	REGISTRY
69	RN	218437-40-2	REGISTRY
70	RN	218437-39-9	REGISTRY
71	RN	218437-38-8	REGISTRY
72	RN	218437-37-7	REGISTRY
73	RN	218437-36-6	REGISTRY
74	RN	218437-35-5	REGISTRY
75	RN	218437-34-4	REGISTRY
76	RN	218437-33-3	REGISTRY
77	RN	218437-32-2	REGISTRY
78	RN	218437-31-1	REGISTRY
79	RN	218437-30-0	REGISTRY
80	RN	218437-25-3	REGISTRY
81	RN	218437-24-2	REGISTRY
82	RN	218437-23-1	REGISTRY
83	RN	218437-21-9	REGISTRY
84	RN	218437-19-5	REGISTRY
85	RN	218437-17-3	REGISTRY
86	RN	218437-15-1	REGISTRY
87	RN	218437-13-9	REGISTRY
88	RN	218437-11-7	REGISTRY
89	RN	218437-10-6	REGISTRY
90	RN	218437-09-3	REGISTRY
91	RN	218437-08-2	REGISTRY
92	RN	218437-07-1	REGISTRY
93	RN	218437-06-0	REGISTRY
94	RN	218437-05-9	REGISTRY
95	RN	218437-04-8	REGISTRY
96	RN	218437-03-7	REGISTRY
97	RN	218437-02-6	REGISTRY
98	RN	218437-01-5	REGISTRY
99	RN	173388-33-5	REGISTRY
100	RN	128332-75-2	REGISTRY
101	RN	128312-98-1	REGISTRY
102	RN	128312-74-3	REGISTRY
103	RN	114694-10-9	REGISTRY

=> d ide can 1 10 20 30 37 38 45 50 60 70 80 90 99-103

L67 ANSWER 1 OF 103 REGISTRY COPYRIGHT 2002 ACS

RN 401593-62-2 REGISTRY

CN Cyclopentanone, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]-2-methylene- (9CI) (CA INDEX NAME)

FS STEREOSEARCH


MF C28 H40 O3

SR CA

LC STN Files: CA, CAPLUS

Absolute stereochemistry.
Double bond geometry as shown.

Sample
compounds
from hits



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 136:194682

L67 ANSWER 10 OF 103 REGISTRY COPYRIGHT 2002 ACS

RN 266344-40-5 REGISTRY

CN Cyclopentanone, 3-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propyl]-2-methylene-, (3R)- (9CI) (CA INDEX NAME)


FS STEREOSEARCH

MF C28 H40 O3

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 132:322032

L67 ANSWER 20 OF 103 REGISTRY COPYRIGHT 2002 ACS
 RN 266344-14-3 REGISTRY
 CN 2-Pyrrolidinone, 3-[(2S)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-bis[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]-1-hydroxypropyl]-1-hydroxy- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C38 H67 N O5 Si2
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.
 Double bond geometry as shown.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 132:322032

L67 ANSWER 30 OF 103 REGISTRY COPYRIGHT 2002 ACS
 RN 266343-81-1 REGISTRY
 CN Silane, [[(1R,3S,5Z)-4-methylene-5-[(2E)-[(1R,3aS,7aR)-octahydro-7a-methyl-1-[(2E)-1-methyl-2-[3-methyl-2-[(trimethylsilyl)oxy]-2-cyclopenten-1-ylidene]ethyl]-4H-inden-4-ylidene]ethylidene]-1,3-cyclohexanediyl]bis(oxy)]bis[(1,1-dimethylethyl)dimethyl- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C43 H76 O3 Si3
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.
 Double bond geometry as shown.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 132:322032

L67 ANSWER 37 OF 103 REGISTRY COPYRIGHT 2002 ACS
RN 218598-74-4 REGISTRY
CN 1,3-Cyclohexanediol, 5-[(2E)-[(1R,3aS,7aR)-octahydro-1-[(1S)-2-hydroxy-2-(2-hydroxy-3,3-dimethylcyclopentyl)-1-methylethyl]-7a-methyl-4H-inden-4-ylidene]ethylidene]-4-methylene-, (1R,3S,5Z)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C29 H46 O4
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


1 REFERENCES IN FILE CA (1967 TO DATE)

1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 130:81699

L67 ANSWER 38 OF 103 REGISTRY COPYRIGHT 2002 ACS
 RN 218437-96-8 REGISTRY
 CN Cyclopentanone, 2-(acetyloxy)-5-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-bis[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-2-methyl-, (5E)- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C42 H70 O5 Si2
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.
 Double bond geometry as shown.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 130:81699

L67 ANSWER 45 OF 103 REGISTRY COPYRIGHT 2002 ACS
 RN 218437-64-0 REGISTRY
 CN Cyclohexanone, 2-[3-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]butylidene]-, (2Z)- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C29 H42 O3
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.
 Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 130:81699

L67 ANSWER 50 OF 103 REGISTRY COPYRIGHT 2002 ACS

RN 218437-59-3 REGISTRY

CN 1,3-Cyclohexanediol, 5-[(2E)-[(1R,3aS,7aR)-1-[(1R,2E)-2-[(2S,3R)-2,3-dihydroxy-3-methylcyclopentylidene]-1-methylethyl]octahydro-7a-methyl-4H-inden-4-ylidene]ethylidene]-4-methylene-, (1R,3S,5Z)- (9CI) (CA INDEX NAME)


FS STEREOSEARCH

MF C28 H42 O4

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 130:81699

L67 ANSWER 60 OF 103 REGISTRY COPYRIGHT 2002 ACS
 RN 218437-49-1 REGISTRY
 CN Cyclohexanone, 6-[(1.alpha.,3.beta.,5Z,7E)-1,3-dihydroxy-9,10-secochola-5,7,10(19)-trien-24-ylidene]-2-hydroxy-2-methyl-, (2R,6E)- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C31 H46 O4
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.
 Double bond geometry as shown.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 130:81699

L67 ANSWER 70 OF 103 REGISTRY COPYRIGHT 2002 ACS
 RN 218437-39-9 REGISTRY
 CN Cycloheptanone, 2-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-, (2E)- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C29 H42 O3
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.
 Double bond geometry as shown.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 130:81699

L67 ANSWER 80 OF 103 REGISTRY COPYRIGHT 2002 ACS
RN 218437-25-3 REGISTRY
CN Cyclopentanone, 5-[(2S)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-2-hydroxy-2-propyl-, (2S,5E)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C30 H44 O4
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 130:81699

L67 ANSWER 90 OF 103 REGISTRY COPYRIGHT 2002 ACS
 RN 218437-09-3 REGISTRY
 CN Cyclopentanone, 5-[(2S)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-[(3S,5R)-3,5-dihydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-7a-methyl-1H-inden-1-yl]propylidene]-2-hydroxy-2-methyl-, (2R,5E)- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C28 H40 O4
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.
 Double bond geometry as shown.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 130:81699

L67 ANSWER 99 OF 103 REGISTRY COPYRIGHT 2002 ACS
 RN 173388-33-5 REGISTRY
 CN 1,3-Cyclohexanediol, 4-methylene-5-[[octahydro-1-[2-(4-hydroxy-4-methyl-2-cyclopenten-1-yl)-1-methylethyl]-7a-methyl-4H-inden-4-ylidene]ethylidene]-, [1R-[1.alpha.[R*(1S*,4R*)],3a.beta.,4E[Z(1R*,3S*)],7a.alpha.]]- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C28 H42 O3
 SR CA
 LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.
 Double bond geometry as shown.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 124:146588

L67 ANSWER 100 OF 103 REGISTRY COPYRIGHT 2002 ACS
RN 128332-75-2 REGISTRY
CN Cyclohexanol, 1-[(1.alpha.,3.beta.,5Z,7E)-1,3-bis[[(1,1-dimethylethyl)dimethylsilyl]oxy]-9,10-secochola-5,7,10(19)-trien-24-yl]-(9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 9,10-Secocholane, cyclohexanol deriv.
MF C42 H76 O3 Si2
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 113:78822

L67 ANSWER 101 OF 103 REGISTRY COPYRIGHT 2002 ACS
 RN 128312-98-1 REGISTRY
 CN Cyclohexanol, 1-[(1.alpha.,3.beta.,5E,7E)-1,3-bis[[1,1-dimethylethyl]dimethylsilyl]oxy]-9,10-secochola-5,7,10(19)-trien-24-yl]-
 (9CI) (CA INDEX NAME)
 OTHER CA INDEX NAMES:
 CN 9,10-Secocholane, cyclohexanol deriv.
 MF C42 H76 O3 Si2
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 113:78822

L67 ANSWER 102 OF 103 REGISTRY COPYRIGHT 2002 ACS
 RN 128312-74-3 REGISTRY
 CN 9,10-Secochola-5,7,10(19)-triene-1,3-diol, 24-(1-hydroxycyclohexyl)-,
 (1.alpha.,3.beta.,5Z,7E)- (9CI) (CA INDEX NAME)
 MF C30 H48 O3
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1967 TO DATE)
4 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 119:125211

REFERENCE 2: 119:124825

REFERENCE 3: 115:64738

REFERENCE 4: 113:78822


L67 ANSWER 103 OF 103 REGISTRY COPYRIGHT 2002 ACS

RN 114694-10-9 REGISTRY

CN 9,10-Secochola-5,7,10(19)-triene-1,3-diol, 24-(1-hydroxycyclopentyl)-,
(1.alpha.,3.beta.,5Z,7E)- (9CI) (CA INDEX NAME)

MF C29 H46 O3

SR CA

LC STN Files: BEILSTEIN*, CA, CAPLUS, CASREACT, TOXCENTER, USPATFULL
(*File contains numerically searchable property data)

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1967 TO DATE)
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 112:21201

REFERENCE 2: 109:55060